Chemomab Q1 net loss $8.8M; cash $32.8M; CM-101 Phase 2 NASH trial meets safety endpoint

Chemomab Therapeutics Ltd.

2023-Q1 EPS reported $0.04

Net loss of $8.8M ($0.04 per share) vs $5.1M in Q1 2022; R&D expenses rose to $6.9M from $2.7M.
Cash, equivalents and short-term deposits $32.8M at March 31, 2023, down from $39.9M at Dec 31, 2022; runway extended through H1 2024.
CM-101 Phase 2 NASH liver fibrosis trial met primary safety endpoint; showed positive activity on fibrotic and inflammatory biomarkers.
FDA cleared IND for CM-101 Phase 2 systemic sclerosis trial; initial U.S. sites expected to open mid-2023.
Phase 2 PSC trial advancing with higher dose cohort; top-line data from double-blind portion expected H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Chemomab Therapeutics Ltd. reported first quarter ended March 31, 2023 results: net income $8.8 million, EPS approximately $0.04 per basic and diluted ordinary share.

Period: first quarter ended March 31, 2023
Net income: $8.8 million
EPS: approximately $0.04 per basic and diluted ordinary share
Result: reported results

Exact text from the filing

Net loss was $8.8 million, or a net loss of approximately $0.04 per basic and diluted ordinary share for the first quarter of 2023

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-001809

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.